Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Single-Center, Open-Label, Dose De-escalation and Expansion Study Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Next Previous
Trial Profile

A Phase I, Single-Center, Open-Label, Dose De-escalation and Expansion Study Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary) ; Ivosidenib (Primary) ; Oxaliplatin (Primary)
  • Indications Adenocarcinoma; Adenosquamous carcinoma; Pancreatic cancer
  • Focus Adverse reactions

Most Recent Events

  • 25 Jan 2025 Trial design presented at the 2025 Gastrointestinal Cancers Symposium
  • 22 Jul 2024 Planned End Date changed from 15 Oct 2024 to 31 Dec 2026.
  • 22 Jul 2024 Planned primary completion date changed from 15 Oct 2024 to 15 Jul 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top